Drug royalty sales supercharged by sinking biotech valuations, says leading dealmaker
Following the firm’s recent $115 million investment, Sagard Healthcare Royalty Partners’ Ali Alagheband says a flurry of activity is underway in the market
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Register now
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.
Subscribe now
Already have access? Login below
